KARACHI: Pakistani researchers working under government-approved projects have expressed confidence that they can develop a vaccine for coronavirus, but added that the process could take nine months or more.
As of Sunday, authorities said 50 people had died while 3,200 had tested positive for the virus in the country.
“We are actively engaged in vaccination development. It will be clinical trials on animals first and then humans... the process will not take less than nine months, could even take more than that.”
Dr. Javed Akram, who is leading a government-sanctioned series of clinical trials for the vaccine, told Arab News on Saturday.
Dr. Akram, who is also a Vice-Chancellor of the University of Health Sciences (UHS) in Lahore, said that the process began on Friday after Professor Dr. Atta-ur-Rahman, Chairman of Prime Minister’s National Task Force on Science and Technology authorized him to lead the clinical trials for the vaccine, last week.
It follows a breakthrough by Pakistani scientists and researchers who detected a genetic mutation of the coronavirus through genome sequencing – a process which reveals the order of bases present in the entire genome of an organism and is an essential step in the necessary research for clinical diagnosis and the development of vaccines and drugs.
Since the breakthrough, Dr. Akram said they had conducted genome sequencing for the coronavirus in two separate trials, in Karachi and Lahore.
Experts say the studies reveal that the virus is mutative, which means that “it can adjust to local conditions” which are slightly different from Wuhan – the epicenter of the epidemic in China which led to the coronavirus outbreak, killing more than 65,000 and impacting more than a million people across the world.
“The process revealed that the sequence of this virus is slightly different from the Wuhan virus with few mutations,” Professor Dr. Saeed Khan, a virologist at Dow University of Health Sciences (DUHS) in Karachi, and a member of the team that conducted the trials told Arab News.
On Wednesday, DUHS said it had conducted the genetic sequencing of the virus – obtained from a locally-infected 15-year-old boy – by collaborating with the International Center for Chemical and Biological Sciences (ICCBS) in Karachi.
Dr. Akram confirmed that the tests showed that the coronavirus’ strain in Pakistan was mutative but said that it was not “clinically significant.”
“We have also done (genetic sequencing) and (it was detected) that mutations of the virus are taking place, but they are not very significant because these changes are not major – only 3-5 percent mutations are detected,” he said.
The research further revealed that two types of coronavirus strains, S-Strain and L-Strain, are spreading around the world.
“The study shows that the L-strain was derived from the older S-strain. The genetic sequencing shows that the virus was L-strain that is more aggressive and spreads rapidly,” Professor Khan said.
DUHS now plans to develop the vaccines, which researchers say requires funding – a request for which has been sent to the relevant authorities.
“We want to develop a vaccine that would be effective for all strains of the virus,” Professor Khan said.
Pakistani scientists get government nod to develop coronavirus vaccine
https://arab.news/p8yxp
Pakistani scientists get government nod to develop coronavirus vaccine
- Researchers say process awaits funding, could take nine months or more
- Clinical trials conducted after experts detected a genetic mutation of the virus through genome sequencing
Pakistani stocks breach 176,000 points barrier as investors expect further rate cuts
- Pakistani financial analyst attributes surge to falling inflation, investors expecting further policy rate cuts
- Pakistan’s finance ministry said Thursday that inflation had slowed to 5.6 percent year-on-year in December
KARACHI: Pakistani stocks continued their bullish run on Thursday, breaching the 176,000 points barrier for the first time after trading ended, with analysts attributing the surge to investors expecting further cuts in the policy rate.
The KSE-100 benchmark gained 2,301.17 points at close of business on Thursday, marking an increase of 1.32 percent to settle at 176,355.49 points.
Pakistan’s central bank cut its key policy rate by 50 basis points to 10.5 percent last month, breaking a four-meeting hold in a move that surprised markets. Pakistan’s consumer price inflation slowed to 5.6 percent year-on-year in December, while prices fell on a monthly basis as per data from the finance ministry.
“Upbeat data for consumer price index (CPI) inflation at 5.6pc in December 2025 [with] investors expecting a further State Bank of Pakistan rate cuts on falling inflation data,” Ahsan Mehanti, CEO of Arif Habib Commodities Ltd., told Arab News.
The stock market witnessed a trading volume of 1,402.650 million shares, with a traded value of Rs48.424 billion ($173 million), compared with 957.239 million shares valued at Rs44.231 billion ($158 million) during the previous session.
Topline Securities, a leading brokerage firm in Pakistan, credited the surge to strong buying at the first session.
“This positivity can be accredited to buying by local institutions on the start of the new calendar year,” it said.
Pakistan’s Finance Adviser Khurram Schehzad highlighted that the bullish trend at the stock market reflected “strong investor confidence.”
“With lower inflation, affordable fuel, stronger reserves, rising digitization and a buoyant capital market, Pakistan’s economic outlook is clearly improving--supporting greater confidence, better investment sentiment and more positive momentum for 2026,” he said on social media platform X.
